ABSTRACT
Response rates with conventional chemotherapy are low in myeloma.1,2 The attainment of sustained remission with high-dose therapy and syngeneic bone marrow transplantation (BMT) showed that there was a dose-response relationship in myeloma.3 Later, McElwain and Powles 4
demonstrated the profound activity of highdose melphalan in myeloma and plasma cell leukemia, obtaining excellent responses, including near-complete remission (CR), with 100-140 mg/m2 melphalan as a single agent.
